Reuters logo
BRIEF-AB Science: CHMP adopts negative opinion for Masitinib marketing authorization
September 14, 2017 / 5:36 PM / 3 months ago

BRIEF-AB Science: CHMP adopts negative opinion for Masitinib marketing authorization

Sept 14 (Reuters) - AB SCIENCE SA:

* REG-AB SCIENCE ANNOUNCES THAT CHMP ADOPTED A NEGATIVE OPINION FOR MASITINIB MARKETING AUTHORIZATION IN INDOLENT SYSTEMIC MASTOCYTOSIS AFTER REASSESSMENT

* CHMP CONSIDERED THAT THERE WERE TOO MANY UNCERTAINTIES THAT PRECLUDED THE BENEFIT-RISK ASSESSMENT‍​

* TO CONFIRM FIRST STUDY RESULTS WITH CONFIRMATORY STUDY IN MASTOCYTOSIS PATIENTS UNRESPONSIVE TO SYMPTOMATIC TREATMENT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below